Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

quizartinib dihydrochloride

View Patient Information
The dihydrochloride salt form of quizartinib, an orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:AC010220 2HCl
N-(5-tert-butyl-isoxazol-3-yl)-N'-(4-(7-(2-morpholin-4-ylethoxy)imidazo(2,1-b)(1,3)benzothiazol-2-yl)phenyl)urea dihydrochloride
US brand name:Vanflyta
Code name:AC220 2HCl
Chemical structure:urea, N-(5-(1,1-dimethylethyl)-3-isoxazolyl)-N'-(4-(7-(2-(4-morpholinyl) ethoxy)imidazo(2,1-b)benzothiazol-2-yl)phenyl)-, hydrochloride (1:2)
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search